The U.S. Food and Drug Administration has approved Linzess, a treatment for people suffering with chronic idiopathic constipation.
Designed by Iron Pharmaceuticals in partnership with Allergan, the drug has three approved dosages in 290 mcg, 145 mcg and now 72 mcg. It is also used in the treatment of irritable bowel syndrome.
“Linzess is the branded prescription market leader in the treatment of adult patients with irritable bowel syndrome and chronic idiopathic constipation," Tom McCourt, chief commercial officer at Ironwood, said. "We believe the availability of a 72 mcg does will enhance the product’s utility to physicians in treating adults.”
McCourt said the approval is testimony to the ongoing commitment of the organizations to enhance patient care and refine the treatment of gastrointestinal disorders.
Linzess for constipation receives FDA approval
Alerts Sign-up